Standards; Enzyme Activators and Inhibitors; Pharmaceutical/API Drug Impurities/Metabolites;
应用
1,5,-Dihydroxyempagliflozin is an impurity of Empagliflozin (E521510) which is a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats.
参考文献
Thomas, L., et al.: Diabetes. Obesity. Metabol. 14, 94 (2012); Grempler, R., et al.: Diabetes. Obesity. Metabol., 14, 83 (2012)